SP 18904

Drug Profile

SP 18904

Latest Information Update: 27 Jul 2000

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Shaman Pharmaceuticals
  • Developer Metabolex; Shaman Pharmaceuticals
  • Class Antihyperglycaemics; Naphthoquinones
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 27 Jul 2000 Discontinued-Preclinical for Type-2 diabetes mellitus in USA (PO)
  • 13 Jul 2000 Metabolex acquired licence to the Diabetes drug development programme from Shaman Pharmaceuticals
  • 10 Mar 1999 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top